Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®
"At The Liver Meeting® we will present initial results from
Part A of a Phase 1 study indicating that ARC-AAT is well-tolerated and
induces deep, durable, and dose-dependent knockdown of circulating
alpha-1 antitrypsin. In addition, we will present mouse model data
showing that over time ARC-AAT had the desired effect of preventing
liver production of mutant Z-alpha1 antitrypsin polymers and reversing
liver disease," said
Oral Presentation:
RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model
- Publication Number: 124
- Session: Parallel 19: Pediatric and Metabolic Liver Diseases: Basic and Translational
-
Session Date and Time:
November 13, 2016 from4:45 PM to 6:15 PM -
Authors:
Christine Wooddell , et al.
Poster Presentation:
RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers
- Publication Number: LB-24
- Session: Late-Breaking Poster Session
-
Session Date and Time:
November 13, 2016 from8:00 AM to 5:30 PM -
Authors:
Alice Turner , et al.
Additional details including presentation abstracts can be found on the AASLD website at http://www.aasld.org/. A copy of presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations conclude.
About ARC-AAT
Arrowhead's ARC-AAT is being investigated for the treatment of liver
disease associated with alpha-1 antitrypsin deficiency (AATD), a rare
genetic disease that severely damages the liver and lungs of affected
individuals. The mean estimated prevalence of AATD in the
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of
Source:
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020005546/en/
626-304-3400
ir@arrowheadpharma.com
or
Investor
Relations:
646-378-2947
ir@arrowheadpharma.com
or
Media:
212-845-4272
matt.middleman@russopartnersllc.com
Source:
News Provided by Acquire Media